Related Experiment Videos
Tc-99m sestamibi scintigraphy in multiple myeloma
F Di Gennaro1, L Catalano, L Pace
1Nuclear Medicine Center, Department of Biomorphological and Functional Sciences, University Federico II, Napoli, Italy.
Clinical Nuclear Medicine
|February 13, 1999
Summary
Technetium Tc-99m sestamibi imaging can identify bone marrow and osteolytic involvement in multiple myeloma patients. This nuclear medicine technique shows promise for diagnosing skeletal complications in this hematologic malignancy.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Skeletal involvement, including osteolytic lesions and bone marrow infiltration, is a common complication of multiple myeloma.
Observation:
- Tc-99m sestamibi imaging was performed in two patients diagnosed with multiple myeloma.
- The imaging revealed distinct patterns of radiotracer uptake in both individuals.
Findings:
- One patient exhibited focal areas of increased Tc-99m sestamibi uptake, suggestive of localized disease.
- The second patient demonstrated diffuse skeletal uptake, indicating more widespread bone marrow involvement.
- These findings suggest Tc-99m sestamibi can visualize bone marrow and osteolytic lesions in multiple myeloma.
Implications:
- Tc-99m sestamibi imaging may serve as a valuable tool for assessing the extent of skeletal involvement in multiple myeloma.
- This imaging modality could aid in diagnosis, staging, and monitoring treatment response in patients with multiple myeloma.
- Further research is warranted to establish the sensitivity and specificity of Tc-99m sestamibi for multiple myeloma bone disease.